Weber JS - Search Results

1

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

Hodi FS, Hwu WJ, Kefford R, Weber JS, Daud A, Hamid O, Patnaik A, Ribas A, Robert C, Gangadhar TC, Joshua AM, Hersey P, Dronca R, Joseph R, Hille D, Xue D, Li XN, Kang SP, Ebbinghaus S, Perrone A, Wolchok JD. Hodi FS, et al. Among authors: weber js. J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7. J Clin Oncol. 2016. PMID: 26951310 Free PMC article. Clinical Trial.

2

Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.

Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, et al. Weber J, et al. J Clin Oncol. 1993 Mar;11(3):499-506. doi: 10.1200/JCO.1993.11.3.499. J Clin Oncol. 1993. PMID: 7680375 Clinical Trial.

3

Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.

Guleria AS, Yang JC, Topalian SL, Weber JS, Parkinson DR, MacFarlane MP, White RL, Steinberg SM, White DE, Einhorn JH, et al. Guleria AS, et al. Among authors: weber js. J Clin Oncol. 1994 Dec;12(12):2714-22. doi: 10.1200/JCO.1994.12.12.2714. J Clin Oncol. 1994. PMID: 7989949 Clinical Trial.

4

Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma.

Lee P, Wang F, Kuniyoshi J, Rubio V, Stuges T, Groshen S, Gee C, Lau R, Jeffery G, Margolin K, Marty V, Weber J. Lee P, et al. J Clin Oncol. 2001 Sep 15;19(18):3836-47. doi: 10.1200/JCO.2001.19.18.3836. J Clin Oncol. 2001. PMID: 11559721 Clinical Trial.

5

Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma.

Sanderson K, Scotland R, Lee P, Liu D, Groshen S, Snively J, Sian S, Nichol G, Davis T, Keler T, Yellin M, Weber J. Sanderson K, et al. J Clin Oncol. 2005 Feb 1;23(4):741-50. doi: 10.1200/JCO.2005.01.128. Epub 2004 Dec 21. J Clin Oncol. 2005. PMID: 15613700

6

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events.

Weber J. Weber J. Oncologist. 2007 Jul;12(7):864-72. doi: 10.1634/theoncologist.12-7-864. Oncologist. 2007. PMID: 17673617 Free article. Review.

7

Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma.

Thompson JA, Curti BD, Redman BG, Bhatia S, Weber JS, Agarwala SS, Sievers EL, Hughes SD, DeVries TA, Hausman DF. Thompson JA, et al. Among authors: weber js. J Clin Oncol. 2008 Apr 20;26(12):2034-9. doi: 10.1200/JCO.2007.14.5193. Epub 2008 Mar 17. J Clin Oncol. 2008. PMID: 18347008 Clinical Trial.

8

CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.

Phan GQ, Weber JS, Sondak VK. Phan GQ, et al. Among authors: weber js. Ann Surg Oncol. 2008 Nov;15(11):3014-21. doi: 10.1245/s10434-008-0104-y. Epub 2008 Aug 21. Ann Surg Oncol. 2008. PMID: 18716842 Review.

9

Phase I/II study of ipilimumab for patients with metastatic melanoma.

Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Weber JS, et al. J Clin Oncol. 2008 Dec 20;26(36):5950-6. doi: 10.1200/JCO.2008.16.1927. Epub 2008 Nov 17. J Clin Oncol. 2008. PMID: 19018089 Clinical Trial.

10

Recent advances using anti-CTLA-4 for the treatment of melanoma.

Sarnaik AA, Weber JS. Sarnaik AA, et al. Among authors: weber js. Cancer J. 2009 May-Jun;15(3):169-73. doi: 10.1097/PPO.0b013e3181a7450f. Cancer J. 2009. PMID: 19556898 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

316 results

Search Page